A csontok óriássejtes tumoráról.

Translated title of the contribution: Giant-cell tumor of the bone

M. Szendrői, I. Antal, János Kiss

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The giant-cell tumor of bone (GCT) is an aggressive benign, potentially malignant lesion, which biological behaviour is unpredictable. Its aggressivity is usually increasing through the recurrences and is related to the mitotic activity, the excessive metalloproteinase expression and to the alterations in different oncogens of the tumor cells. Statistically, 80% of the GCT-s have a benign course, with a local recurrence rate of 10-50%; about 10% of GCT-s undergo malignant transformation through their recurrences and 1-4% give pulmonary metastases even in case of a benign histology. Despite of the frequent recurrences, adequate treatment results in 96% to 98% cure in patients with GCT. The goal of surgery should be both in primary and recurrent cases: joint-sparing and careful curettage with use of adjuvants (bone cement and phenol, etc.) for decreasing the rate of recurrences. Resection is only in case of extensive joint destruction or malignancy indicated. Radiotherapy with modern supervoltage equipment minimalized the occurrence of secondary malignant transformation, however, its use is only in locations difficult for surgery (vertebra, sacrum, pelvis) recommended.

Original languageHungarian
Pages (from-to)1171-1177
Number of pages7
JournalOrvosi Hetilap
Volume144
Issue number24
Publication statusPublished - Jun 15 2003

Fingerprint

Giant Cell Tumor of Bone
Recurrence
Joints
Sacrum
Bone Cements
Curettage
Metalloproteases
Phenol
Pelvis
Carcinogens
Neoplasms
Histology
Spine
Radiotherapy
Neoplasm Metastasis
Equipment and Supplies
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A csontok óriássejtes tumoráról. / Szendrői, M.; Antal, I.; Kiss, János.

In: Orvosi Hetilap, Vol. 144, No. 24, 15.06.2003, p. 1171-1177.

Research output: Contribution to journalArticle

Szendrői, M, Antal, I & Kiss, J 2003, 'A csontok óriássejtes tumoráról.', Orvosi Hetilap, vol. 144, no. 24, pp. 1171-1177.
Szendrői, M. ; Antal, I. ; Kiss, János. / A csontok óriássejtes tumoráról. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 24. pp. 1171-1177.
@article{8f98fb959ab544f981a1cfeb7687e794,
title = "A csontok {\'o}ri{\'a}ssejtes tumor{\'a}r{\'o}l.",
abstract = "The giant-cell tumor of bone (GCT) is an aggressive benign, potentially malignant lesion, which biological behaviour is unpredictable. Its aggressivity is usually increasing through the recurrences and is related to the mitotic activity, the excessive metalloproteinase expression and to the alterations in different oncogens of the tumor cells. Statistically, 80{\%} of the GCT-s have a benign course, with a local recurrence rate of 10-50{\%}; about 10{\%} of GCT-s undergo malignant transformation through their recurrences and 1-4{\%} give pulmonary metastases even in case of a benign histology. Despite of the frequent recurrences, adequate treatment results in 96{\%} to 98{\%} cure in patients with GCT. The goal of surgery should be both in primary and recurrent cases: joint-sparing and careful curettage with use of adjuvants (bone cement and phenol, etc.) for decreasing the rate of recurrences. Resection is only in case of extensive joint destruction or malignancy indicated. Radiotherapy with modern supervoltage equipment minimalized the occurrence of secondary malignant transformation, however, its use is only in locations difficult for surgery (vertebra, sacrum, pelvis) recommended.",
author = "M. Szendrői and I. Antal and J{\'a}nos Kiss",
year = "2003",
month = "6",
day = "15",
language = "Hungarian",
volume = "144",
pages = "1171--1177",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "24",

}

TY - JOUR

T1 - A csontok óriássejtes tumoráról.

AU - Szendrői, M.

AU - Antal, I.

AU - Kiss, János

PY - 2003/6/15

Y1 - 2003/6/15

N2 - The giant-cell tumor of bone (GCT) is an aggressive benign, potentially malignant lesion, which biological behaviour is unpredictable. Its aggressivity is usually increasing through the recurrences and is related to the mitotic activity, the excessive metalloproteinase expression and to the alterations in different oncogens of the tumor cells. Statistically, 80% of the GCT-s have a benign course, with a local recurrence rate of 10-50%; about 10% of GCT-s undergo malignant transformation through their recurrences and 1-4% give pulmonary metastases even in case of a benign histology. Despite of the frequent recurrences, adequate treatment results in 96% to 98% cure in patients with GCT. The goal of surgery should be both in primary and recurrent cases: joint-sparing and careful curettage with use of adjuvants (bone cement and phenol, etc.) for decreasing the rate of recurrences. Resection is only in case of extensive joint destruction or malignancy indicated. Radiotherapy with modern supervoltage equipment minimalized the occurrence of secondary malignant transformation, however, its use is only in locations difficult for surgery (vertebra, sacrum, pelvis) recommended.

AB - The giant-cell tumor of bone (GCT) is an aggressive benign, potentially malignant lesion, which biological behaviour is unpredictable. Its aggressivity is usually increasing through the recurrences and is related to the mitotic activity, the excessive metalloproteinase expression and to the alterations in different oncogens of the tumor cells. Statistically, 80% of the GCT-s have a benign course, with a local recurrence rate of 10-50%; about 10% of GCT-s undergo malignant transformation through their recurrences and 1-4% give pulmonary metastases even in case of a benign histology. Despite of the frequent recurrences, adequate treatment results in 96% to 98% cure in patients with GCT. The goal of surgery should be both in primary and recurrent cases: joint-sparing and careful curettage with use of adjuvants (bone cement and phenol, etc.) for decreasing the rate of recurrences. Resection is only in case of extensive joint destruction or malignancy indicated. Radiotherapy with modern supervoltage equipment minimalized the occurrence of secondary malignant transformation, however, its use is only in locations difficult for surgery (vertebra, sacrum, pelvis) recommended.

UR - http://www.scopus.com/inward/record.url?scp=0043198301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043198301&partnerID=8YFLogxK

M3 - Article

C2 - 12866146

AN - SCOPUS:0043198301

VL - 144

SP - 1171

EP - 1177

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 24

ER -